Evidence map›Paper›PMID 39414703›Full record

ArticleAnnals of surgical oncology2025

Racial Disparities in Liver Transplant for Hepatitis C-Associated Hepatocellular Carcinoma.

Frances J Bennett, Jessica M Keilson, Michael K Turgeon, Kailey M Oppat, Emilie A K Warren, Shimul A Shah, Vatche G Agopian, Joseph F Magliocca, Andrew Cameron, Susan L Orloff and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Frances J BennettDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Jessica M KeilsonDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Michael K TurgeonDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Kailey M OppatDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Emilie A K WarrenDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Shimul A ShahDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Vatche G AgopianDepartment of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Joseph F MaglioccaDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Andrew CameronDepartment of Surgery, Johns Hopkins, Baltimore, MD, USA.
Susan L OrloffDepartment of Surgery, Oregon Health and Science University, Portland, OR, USA.
Chandrashekhar A KubalDepartment of Surgery, Indiana University Health, Indianapolis, IN, USA.
Robert M CannonDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Mohamed E AkoadDepartment of Surgery, Lahey Hospital and Medical Center, Boston, MA, USA.
Juliet EmamaulleeDepartment of Surgery, Keck Hospital of University of Southern California, Los Angeles, CA, USA.
Federico AucejoDepartment of Surgery, Cleveland Clinic, Cleveland, OH, USA.
Parsia A VagefiDepartment of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.
Mindie H NguyenDepartment of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
Kiran DhanireddyDepartment of Surgery, Tampa General Hospital, Tampa, FL, USA.
Marwan M KazimiDepartment of Surgery, Piedmont Healthcare, Atlanta, GA, USA.
Christopher J SonnendayDepartment of Surgery, University of Michigan, Ann Arbor, MI, USA.
David P FoleyDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Marwan AbdouljoudDepartment of Surgery, Henry Ford Health System, Detroit, MI, USA.
Debra L SudanDepartment of Surgery, Duke University School of Medicine, Durham, NC, USA.
Abhinav HumarDepartment of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
M B Majella DoyleDepartment of Surgery, Washington University School of Medicine at St. Louis, St. Louis, MO, USA.
William C ChapmanDepartment of Surgery, Washington University School of Medicine at St. Louis, St. Louis, MO, USA.
Shishir K MaithelDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA. smaithe@emory.edu.

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378
6 · The paper itself

Abstract

backgroundIn the United States, hepatitis C virus-associated hepatocellular carcinoma incidence and mortality are highest among minorities. Socioeconomic constraints play a major role in inequitable treatment. We evaluated the association between race/ethnicity and outcomes in a population that overcame treatment barriers.

methodsWe report a retrospective cohort study of 666 patients across 20 institutions in the United States Hepatocellular Carcinoma Liver Transplantation Consortium from 2015 to 2019 with hepatitis C virus-associated hepatocellular carcinoma who completed direct-acting antiviral therapy and underwent liver transplantation. Patients were excluded if they had a prior liver transplantation, hepatocellular carcinoma recurrence, no prior liver-directed therapy, or if race/ethnicity data were unavailable. Patients were stratified by race/ethnicity. Primary outcomes were recurrence-free survival and overall survival, and secondary outcome was major postoperative complication.

resultsRace/ethnicity was not associated with differences in 5-year recurrence-free survival (White 90%, Black 88%, Hispanic 92%, Other 87%; p = 0.85), overall survival (White 85%, Black 84%, Hispanic 84%, Other 93%; p = 0.70), or major postoperative complication.

conclusionsRace/ethnicity was not associated with worse oncologic or postoperative outcomes among those who completed direct-acting antiviral therapy and underwent liver transplantation, suggesting that overcoming socioeconomic constraints equalizes outcomes across racial/ethnic groups. Eliminating barriers that prohibit care access among minorities must be a priority.

Indexed as

Carcinoma, HepatocellularHealthcare DisparitiesHepatitis CLiver NeoplasmsLiver TransplantationAgedAntiviral AgentsFemaleFollow-Up StudiesHepacivirusHumansMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesAntiviral AgentsClinical outcomesHepatitis-C virus associated hepatocellular carcinomaLiver transplantationRacial disparitiesRacial/ethnic group minorities

Identifiers

PMID39414703
PMCPMC11931600

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.